{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:07:45Z","timestamp":1758046065434,"version":"3.44.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"DOI":"10.7759\/cureus.92171","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T21:38:11Z","timestamp":1757713091000},"source":"Crossref","is-referenced-by-count":0,"title":["Psoriatic Arthritis Linked to Pembrolizumab in a Lung Cancer Patient: From Oncologist to Rheumatologist"],"prefix":"10.7759","author":[{"given":"Mihaela-Maria","family":"Pasca Fenesan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sirbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Iana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"EU Country Cancer Profile. Romania 2025. (2025). Accessed: February 3, 2025: https:\/\/www.oecd.org\/en\/publications\/eu-country-cancer-profile-romania-2025_8474a271-en.html."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00764-2016","article-title":"Management of stage I and II nonsmall cell lung cancer","volume":"49","author":"McDonald F","year":"2017","unstructured":"McDonald F, De Waele M, Hendriks LE, Faivre-Finn C, Dingemans AC, Van Schil PE. Management of stage I and II nonsmall cell lung cancer. Eur Respir J. 2017, 49:1600764. 10.1183\/13993003.00764-2016","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30030239","article-title":"Stage III non-small-cell lung cancer: an overview of treatment options","volume":"30","author":"Petrella F","year":"2023","unstructured":"Petrella F, Rizzo S, Attili I, et al.. Stage III non-small-cell lung cancer: an overview of treatment options. Curr Oncol. 2023, 30:3160-75. 10.3390\/curroncol30030239","journal-title":"Curr Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit S","year":"2020","unstructured":"Rakshit S, Molina JR. Immunotherapy in patients with autoimmune disease. J Thorac Dis. 2020, 12:7032-8. 10.21037\/jtd-2019-cptn-10","journal-title":"J Thorac Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210045","article-title":"Molecular farming of pembrolizumab and nivolumab","volume":"24","author":"Stark MC","year":"2023","unstructured":"Stark MC, Joubert AM, Visagie MH. Molecular farming of pembrolizumab and nivolumab. Int J Mol Sci. 2023, 24:10045. 10.3390\/ijms241210045","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-33. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE- 042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TS","year":"2019","unstructured":"Mok TS, Wu YL, Kudaba I, et al.. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE- 042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019, 393:1819-30. 10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck M","year":"2021","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50. J Clin Oncol. 2021, 39:2339-49. 10.1200\/JCO.21.00174","journal-title":"J Clin Oncol"},{"key":"ref9","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han YY","year":"2020","unstructured":"Han YY, Liu DD, Li LH. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020, 10:727-42.","journal-title":"Am J Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber JS","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012, 30:2691-7. 10.1200\/JCO.2012.41.6750","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli LC","year":"2017","unstructured":"Cappelli LC, Gutierrez AK, Baer AN, et al.. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017, 76:43-50. 10.1136\/annrheumdis-2016-209595","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111281","article-title":"Adjuvant treatment after neoadjuvant immunotherapy in patients with non-small cell lung cancer","volume":"27","author":"Zhao J","year":"2024","unstructured":"Zhao J, Li Y, Li R, Yao X, Dong X, Su L, Li Y. Adjuvant treatment after neoadjuvant immunotherapy in patients with non-small cell lung cancer. iScience. 2024, 27:111281. 10.1016\/j.isci.2024.111281","journal-title":"iScience"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee H","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, et al.. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023, 389:491-503. 10.1056\/NEJMoa2302983","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach JV","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, et al.. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023, 389:1672-84. 10.1056\/NEJMoa2304875","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative Toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the NEOTORCH randomized clinical trial","volume":"331","author":"Lu S","year":"2024","unstructured":"Lu S, Zhang W, Wu L, et al.. Perioperative Toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the NEOTORCH randomized clinical trial. JAMA. 2024, 331:201-11. 10.1001\/jama.2023.24735","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.12.012","article-title":"Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors","volume":"145","author":"Skribek M","year":"2021","unstructured":"Skribek M, Rounis K, Afshar S, et al.. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Eur J Cancer. 2021, 145:245-54. 10.1016\/j.ejca.2020.12.012","journal-title":"Eur J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.04.007","article-title":"Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature","volume":"108","author":"Ruiz-Ba\u00f1obre J","year":"2017","unstructured":"Ruiz-Ba\u00f1obre J, P\u00e9rez-Pamp\u00edn E, Garc\u00eda-Gonz\u00e1lez J, G\u00f3mez-Caama\u00f1o A, Bar\u00f3n-Duarte FJ, L\u00f3pez-L\u00f3pez R, V\u00e1zquez-Rivera F. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Lung Cancer. 2017, 108:217-21. 10.1016\/j.lungcan.2017.04.007","journal-title":"Lung Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i1.218","article-title":"Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: a case report","volume":"11","author":"Kim S","year":"2023","unstructured":"Kim S, Sun JH, Kim H, et al.. Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: a case report. World J Clin Cases. 2023, 11:218-24. 10.12998\/wjcc.v11.i1.218","journal-title":"World J Clin Cases"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar M","year":"2018","unstructured":"Lidar M, Giat E, Garelick D, et al.. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. 2018, 17:284-9. 10.1016\/j.autrev.2018.01.003","journal-title":"Autoimmun Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/o5nvgv","article-title":"Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre","volume":"39","author":"Gonzalez-Maz\u00f3n I","year":"2021","unstructured":"Gonzalez-Maz\u00f3n I, S\u00e1nchez-Bilbao L, Mart\u00edn-Varillas JL, et al.. Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre. Clin Exp Rheumatol. 2021, 39:612-20. 10.55563\/clinexprheumatol\/o5nvgv","journal-title":"Clin Exp Rheumatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/384051-psoriatic-arthritis-linked-to-pembrolizumab-in-a-lung-cancer-patient-from-oncologist-to-rheumatologist","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T21:38:13Z","timestamp":1757713093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/384051-psoriatic-arthritis-linked-to-pembrolizumab-in-a-lung-cancer-patient-from-oncologist-to-rheumatologist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.92171","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}